扩增抗原特异性供者调节性T细胞预防GVHD
一项1期临床试验在匹配相关供者异基因造血细胞移植中,于移植前2天输注扩增的次要组织相容性抗原特异性供者调节性T细胞,联合西罗莫司为基础预防GVHD。100天II-IV级急性GVHD累积发生率13%,1年及3年中重度慢性GVHD分别为6.7%和20%,总生存率73%。
要点
- mHAg特异性供者Treg联合西罗莫司预防GVHD安全,未观察到DLT,MTD为4×10^5/kg。
- 100天II-IV级急性GVHD累积发生率为13%,1年及3年中重度慢性GVHD分别为6.7%和20%。
- Treg克隆在体外扩增并回输后保持谱系忠实性、持久性及体内扩增能力,支持其作为新型GVHD预防策略。
核心结论
- mHAg特异性扩增供者Treg联合西罗莫司预防GVHD安全可行,初步显示可降低急性及慢性GVHD发生率。
- 扩增的供者Treg克隆可在移植后持续存在并扩增至少1年。
研究设计与样本
- 1期临床试验,采用3+3剂量递增设计,在匹配相关供者异基因造血细胞移植中于移植前2天输注mHAg特异性供者Treg。
- 联合以西罗莫司为基础的药物预防;主要观察剂量限制性毒性,次要及探索性指标包括急慢性GVHD、生存结局及Treg克隆动态。
主要发现
- 未观察到剂量限制性毒性,最大耐受剂量确定为4×10^5/kg。
- 存活者中位随访41.7个月(范围14.5-72.8个月)。
- 100天II-IV级急性GVHD累积发生率为13%;1年中重度慢性GVHD为6.7%,3年为20%;总生存率为73%。
- Treg克隆在培养中扩增,移植后保持谱系忠实性、持久性并可在体内扩增。
关键数值与推荐
- 剂量限制性毒性定义包括:4-5级相关输注反应、4-5级意外器官毒性、III-IV级急性GVHD或治疗相关死亡。
- 最大耐受剂量为4×10^5/kg。
临床怎么用
- 对于匹配相关供者异基因造血细胞移植,可考虑输注mHAg特异性扩增供者Treg联合西罗莫司预防GVHD。
- 该策略的初步疗效和安全性需进一步随机对照试验验证。
局限性
- 随访时间有限,长期安全性及对复发的影响尚未明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Minor histocompatibility antigen (mHAg)-specific alloreactive donor T cells cause graft-versus-host disease (GVHD) in matched related donor allogeneic hematopoietic cell transplantation (HCT). In a phase 1 trial, we expanded and infused (on day -2) mHAg-specific donor regulatory T cells (Treg) together with sirolimus-based pharmacologic prophylaxis to examine the safety and preliminary efficacy of this GVHD prevention approach. We used a 3+3 phase 1 design escalating Treg dose in 4 levels: 0.5 × 105/kg, 1 × 105/kg, 2 × 105/kg, and 4 × 105/kg. Dose-limiting toxicity (DLT) included grade 4 to 5 related infusion reactions, grade 4 to 5 unexpected organ toxicity, grade III to IV acute GVHD, or treatment-related death. Secondary and exploratory measures examined acute and chronic GVHD, survival outcomes, and Treg clone (TCR-seq) expansion in culture, in vivo longevity, and expansion after HCT. Fifteen patients were included (n = 3 each per dose levels 1-3, and n = 6 in dose level 4). No DLTs were observed, and 4 × 105/kg of Treg was identified as maximum tolerated dose. Median follow-up for survivors was 41.7 months (range, 14.5-72.8). The day 100 cumulative incidence of grade II to IV acute GVHD was 13%. National Institutes of Health moderate/severe chronic GVHD by 1 year was 6.7% and by 3 years was 20%. Overall survival was 73%. Treg clones expanded in culture and demonstrated post-HCT lineage fidelity, persistence, and in vivo expansion. This translational trial supports mHAg-specific expanded donor Treg as a novel GVHD prevention strategy and demonstrates that expanded donor Treg clones can persist and expand through 1 year after HCT. This trial was registered at www.clinicaltrials.gov as NCT01795573.
引用
- Pidala J, Cieri N, Schell MJ, et al. Expanded antigen-specific donor regulatory T cells for GVHD prevention. Blood. 2026. PMID: 42322116. doi:10.1182/blood.2025030663
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。